BusinessWorld Online runs a piece on Ozempic as a diabetes drug taken for weight loss. Only a title is available, with no new facts or angle given.
Recap by typeshit. Full story at BusinessWorld Online.
A sponsored-style explainer that walks through semaglutide versus tirzepatide and the post-shortage compounding limits, while featuring telehealth company Mochi Health.
Drugs.com
Eligibility usually starts at a BMI of 30, or 27 with a weight-related condition. The piece also covers costs, side effects and why most people stay on these drugs long term.
Good Morning America looks at GLP-1 use spreading from adults to a growing number of teens being treated for obesity.
ABC News' chief medical correspondent walks through the latest Novo Nordisk GLP-1 medication and what sets it apart from drugs already on the market.
Dr Nadolsky, who treats obesity, responds to what wellness influencer Gary Brecka has said about GLP-1 medications.
South Korea's first homegrown obesity drug won approval, and Hanmi set its price to take on Wegovy and Mounjaro in the local market.
Loading…